Candel Therapeutics Inc (CADL)

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in...

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq:...

Form 8-K - Current report

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or...